Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of budoprutug in primary membranous nephropathy
CTR20261954Phase 2Active
- Sponsor
- Climb Bio
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of budoprutug in idiopathic membranous glomerulonephritis (IMG), sponsored by Climb Bio. Started May 2026; status: active.
02
Drugs
budoprutug
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20261954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261954.